PW

PW MEDTECH GROUP DL-0001

PWE · F · Healthcare / Medical Instruments & Supplies

0.088EUR+0.00 (+0.57%)

Price History

Full chart

Market Stats

Previous Close0.0875
Open0.088
Day Range0.088 – 0.088
52-Week Range0.0805 – 0.1626
Volume0
Market Cap124.96M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield2.79%
Beta0.69
50-Day Avg0.0883
200-Day Avg0.1091

About

PW Medtech Group Limited, an investment holding company, operates as a medical device company in China, India, the Americas, Africa, the rest of Asia, and internationally. It operates in three segments: Infusion Set Business; Blood Purification Business; and Regenerative Medical Biomaterials Business. The company offers advanced infusion sets, such as non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, and insulin needles and pens; hemodialysis and blood purification medical devices; and high-flux hemodialyzers, low-flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. It also provides animal-derived regenerative medical biomaterials and human tissue repair alternative products. The company was formerly known as Pyholding Limited and changed its name to PW Medtech Group Limited in June 2013. PW Medtech Group Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMs. Yue'e Zhang
  • Employees1.43K
  • HeadquartersBuilding 1, Beijing, China, 101204, Germany
  • Websitehttps://www.pwmedtech.com

Leadership

  • Ms. Yue'e ZhangExecutive Chairman & CEO · b. 1963
  • Ms. Tian TianFinancial Director · b. 1982
  • Ms. Ka Man So A.C.I.S., A.C.S., FCIS, FCSCompany Secretary · b. 1974

Financials

Income Statement

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue271.40M536.83M675.08M768.90M823.50M
Growth (%)-+97.80%+25.75%+13.90%+7.10%
Cost of Revenue105.34M238.00M294.19M349.45M416.05M
Gross Profit166.06M298.82M380.90M419.45M407.46M
Gross Margin61.19%55.67%56.42%54.55%49.48%
Operating Expense144.30M230.41M218.28M280.42M305.41M
Operating Income21.76M68.42M162.61M139.03M102.05M
Operating Margin8.02%12.75%24.09%18.08%12.39%
EBITDA-236.80M329.48M347.87M305.57M
EBITDA Margin-44.11%48.81%45.24%37.11%
Net Income739.12M106.04M153.18M150.78M94.37M
Net Income Margin272.34%19.75%22.69%19.61%11.46%
R&D20.25M40.98M41.13M44.12M48.41M
R&D as % of Total Revenue7.46%7.63%6.09%5.74%5.88%
Interest Expense605.00K464.00K154.00K374.00K720.00K
Interest Expense % of Total Revenue0.22%0.09%0.02%0.05%0.09%

Balance Sheet

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.92B4.99B5.15B5.16B5.24B
Total Liabilities122.64M351.56M327.06M357.56M381.52M
Total Equity3.79B3.95B4.04B3.97B3.95B
Cash2.28B1.38B1.59B1.68B1.80B

Cash Flow

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow37.24M269.23M211.03M318.43M240.70M
Capital Expenditure11.32M61.86M81.91M72.08M105.05M
Free Cash Flow25.92M207.38M129.12M246.34M135.65M
Dividends Paid2.06B-71.60M134.37M130.35M
FCF to OCF69.60%77.02%61.19%77.36%56.36%
Dividend Paid to FCF7955.36%-55.45%54.54%96.10%

Key Statistics & Ratios

Market Cap124.96M
Enterprise Value-93.97M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.16
Price / Book0.23
EPS0.00
Book Value0.3555
Revenue (TTM)803.19M
Gross Profit (TTM)384.58M
EBITDA227.97M
Profit Margin5.36%
Operating Margin10.86%
Return on Equity1.80%
Return on Assets1.03%
Shares Outstanding1.43B
Shares Float363.80M
Beta0.69
Dividend Yield2.79%
Dividend Rate0.00
Payout Ratio204.67%

Dividends

20262×
0.00Nov 2, 20260.00Jul 2, 2026
20252×
0.00Nov 3, 20250.01Jul 3, 2025
20242×
0.01Nov 4, 20240.01Jul 4, 2024
20231×
0.01Sep 29, 2023
20212×
0.18Jan 12, 20211.37Jan 6, 2021
20201×
1.37Dec 18, 2020